Biocartis Group (Belgium) Performance
| BCART Stock | EUR 0.29 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Biocartis Group are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biocartis Group NV has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong fundamental drivers, Biocartis Group is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 123.7 M | |
| Total Cashflows From Investing Activities | -3.7 M |
Biocartis |
Biocartis Group Relative Risk vs. Return Landscape
If you would invest 29.00 in Biocartis Group NV on August 24, 2024 and sell it today you would earn a total of 0.00 from holding Biocartis Group NV or generate 0.0% return on investment over 90 days. Biocartis Group NV is generating negative expected returns and assumes 0.0% volatility on return distribution over the 90 days horizon. Simply put, 0% of stocks are less volatile than Biocartis, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biocartis Group Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biocartis Group's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biocartis Group NV, and traders can use it to determine the average amount a Biocartis Group's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BCART |
Based on monthly moving average Biocartis Group is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biocartis Group by adding Biocartis Group to a well-diversified portfolio.
Biocartis Group Fundamentals Growth
Biocartis Stock prices reflect investors' perceptions of the future prospects and financial health of Biocartis Group, and Biocartis Group fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biocartis Stock performance.
| Return On Equity | -48.84 | |||
| Return On Asset | -0.22 | |||
| Profit Margin | (1.07) % | |||
| Operating Margin | (0.85) % | |||
| Current Valuation | 182.31 M | |||
| Shares Outstanding | 93.1 M | |||
| Price To Earning | (9.91) X | |||
| Price To Book | 6.47 X | |||
| Price To Sales | 0.89 X | |||
| Revenue | 48.27 M | |||
| EBITDA | (52.55 M) | |||
| Cash And Equivalents | 53.52 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 128.15 M | |||
| Debt To Equity | 40.40 % | |||
| Book Value Per Share | (1.07) X | |||
| Cash Flow From Operations | (65.72 M) | |||
| Earnings Per Share | (1.24) X | |||
| Total Asset | 142.48 M | |||
| Retained Earnings | (188 M) | |||
| Current Asset | 118 M | |||
| Current Liabilities | 28 M | |||
About Biocartis Group Performance
By analyzing Biocartis Group's fundamental ratios, stakeholders can gain valuable insights into Biocartis Group's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biocartis Group has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biocartis Group has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. The company was founded in 2007 and is headquartered in Mechelen, Belgium. BIOCARTIS operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange. It employs 619 people.Things to note about Biocartis Group NV performance evaluation
Checking the ongoing alerts about Biocartis Group for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biocartis Group NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biocartis Group NV generated a negative expected return over the last 90 days | |
| Biocartis Group NV has some characteristics of a very speculative penny stock | |
| Biocartis Group NV has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 48.27 M. Net Loss for the year was (71.47 M) with loss before overhead, payroll, taxes, and interest of (25.72 M). | |
| Biocartis Group NV has accumulated about 53.52 M in cash with (65.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Biocartis Group's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biocartis Group's stock is overvalued or undervalued compared to its peers.
- Examining Biocartis Group's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biocartis Group's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biocartis Group's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biocartis Group's stock. These opinions can provide insight into Biocartis Group's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biocartis Stock analysis
When running Biocartis Group's price analysis, check to measure Biocartis Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocartis Group is operating at the current time. Most of Biocartis Group's value examination focuses on studying past and present price action to predict the probability of Biocartis Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocartis Group's price. Additionally, you may evaluate how the addition of Biocartis Group to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |